{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:03:37Z","timestamp":1761919417520},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,17]],"date-time":"2010-11-17T00:00:00Z","timestamp":1289952000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1186\/1743-422x-7-324","type":"journal-article","created":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T19:15:27Z","timestamp":1291749327000},"source":"Crossref","is-referenced-by-count":21,"title":["Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon\/ribavirin therapy"],"prefix":"10.1186","volume":"7","author":[{"given":"Mohamed H","family":"Emara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahla E","family":"El-Gammal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamiaa A","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maged M","family":"Bahgat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,17]]},"reference":[{"key":"1068_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2165\/00003495-200868010-00003","volume":"68","author":"H Yuan","year":"2008","unstructured":"Yuan H, Lee W: Nonresponse to treatment for hepatitis C: current management strategies. Drugs 2008, 68: 27-42. 10.2165\/00003495-200868010-00003","journal-title":"Drugs"},{"key":"1068_CR2","first-page":"41","volume":"3","author":"M Mohamed","year":"2004","unstructured":"Mohamed M: Epidemiology of HCV in Egypt. The Afro-Arab Liver journal 2004, 3: 41-52.","journal-title":"The Afro-Arab Liver journal"},{"key":"1068_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H , Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140: 346-355.","journal-title":"Ann Intern Med"},{"key":"1068_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1365-2893.2005.00604.x","volume":"12","author":"M Derbala","year":"2005","unstructured":"Derbala M, Amer A, Bener A, Lopez AC, Omar M, El Ghannam M: Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005, 12: 380-385. 10.1111\/j.1365-2893.2005.00604.x","journal-title":"J Viral Hepat"},{"key":"1068_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1053\/jhep.2001.25172","volume":"34","author":"C Brechot","year":"2001","unstructured":"Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P: Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely \"occult\"? Hepatol 2001, 34: 194-203. 10.1053\/jhep.2001.25172","journal-title":"Hepatol"},{"key":"1068_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJM199907013410104","volume":"341","author":"I Cacciola","year":"1999","unstructured":"Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando M, Raimondo G: Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999, 341: 22-6. 10.1056\/NEJM199907013410104","journal-title":"N Engl J Med"},{"key":"1068_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/hep.510310235","volume":"31","author":"I Cacciola","year":"2000","unstructured":"Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Villari D, de Franchis R, Santantonio T, Brancatelli S, Colucci G, Raimondo G: Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatol 2000, 31: 507-512. 10.1002\/hep.510310235","journal-title":"Hepatol"},{"key":"1068_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jcv.2007.03.006","volume":"39","author":"R Kannangai","year":"2007","unstructured":"Kannangai R, Vivekanandan P, Netski D, Mehta S, Kirk G, Thomasb D, Torbenson M: Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. J Clinical Virol 2007, 39: 101-105. 10.1016\/j.jcv.2007.03.006","journal-title":"J Clinical Virol"},{"key":"1068_CR9","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1016\/S0002-9270(00)02164-X","volume":"95","author":"N De Maria","year":"2000","unstructured":"De Maria N, Colantoni A, Friedlander L, Leandro G, Idilman R, Harig J, Van Thiel D: The impact of previous HBV infection on the course of chronic hepatitis C. Am J Gastroenterol 2000, 95: 3529-3536. 10.1016\/S0002-9270(00)02164-X","journal-title":"Am J Gastroenterol"},{"key":"1068_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s007050050099","volume":"142","author":"A Zignego","year":"1997","unstructured":"Zignego A, Fontana R, Puliti S, Monti M, Careccia G, Giannelli F, Giannini C, Buzzelli G, Brunetto MR, Bonino F, Gentilini P: Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. Arch Virol 1997, 142: 535-544. 10.1007\/s007050050099","journal-title":"Arch Virol"},{"key":"1068_CR11","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/(SICI)1096-9071(199907)58:3<201::AID-JMV3>3.0.CO;2-2","volume":"58","author":"R Fukuda","year":"1999","unstructured":"Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, Kushiyama Y, Uchida Y, Ihihara S, Akagi S, Watanabe M, Kinoshita Y: Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999, 58: 201-207. 10.1002\/(SICI)1096-9071(199907)58:3<201::AID-JMV3>3.0.CO;2-2","journal-title":"J Med Virol"},{"key":"1068_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/1096-9071(200103)63:3<220::AID-JMV1004>3.0.CO;2-3","volume":"63","author":"R Fukuda","year":"2001","unstructured":"Fukuda R, Ishimura N, Hamamoto S, Moritani M, Uchida Y, Ishihara S, Akagi S, Watanabe M, Kinoshita Y: Co-infection by serologically silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol 2001, 63: 220-227. 10.1002\/1096-9071(200103)63:3<220::AID-JMV1004>3.0.CO;2-3","journal-title":"J Med Virol"},{"key":"1068_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000025030","volume":"43","author":"K Nirei","year":"2000","unstructured":"Nirei K, Kaneko M, Moriyama M, Arakawa Y: The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen. Intervirology 2000, 43: 95-101. 10.1159\/000025030","journal-title":"Intervirology"},{"key":"1068_CR14","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/0016-5085(92)91523-7","volume":"103","author":"J Sheu","year":"1992","unstructured":"Sheu J, Huang G, Shih L: Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology 1992, 103: 1322-1327.","journal-title":"Gastroenterology"},{"key":"1068_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/hep.1840170106","volume":"17","author":"P Paterlini","year":"1993","unstructured":"Paterlini P, Driss F, Nalpas B, Pisi E, Franco D, Berthelot P, Brechot C: Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: A study of a low endemic area. Hepatology 1993, 17: 20-29. 10.1002\/hep.1840170106","journal-title":"Hepatology"},{"key":"1068_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jhep.2008.07.005","volume":"49","author":"G Raimondo","year":"2008","unstructured":"Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Crax\u00ec A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Tr\u00e9po C, Villa E, Will H, Zanetti AR, Zoulim F: Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepato 2008, 49: 625-657. 10.1016\/j.jhep.2008.07.005","journal-title":"J Hepato"},{"key":"1068_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T, The French METAVIR Cooperative Study Group: An algorithm for grading activity in chronic hepatitis C. Hepatology 1996, 24: 289-293. 10.1002\/hep.510240201","journal-title":"Hepatology"},{"key":"1068_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jcv.2004.10.016","volume":"33","author":"E Kattab","year":"2005","unstructured":"Kattab E, Chemin I, Vuillermoz I, Vieux C, Mrani S, Guillaud O, Trepo C, Zoulim F: Analysis of HCV co- infection with occult hepatitis B virus in patients undergoing IFN therapy. J Clin Virol 2005, 33: 150-157. 10.1016\/j.jcv.2004.10.016","journal-title":"J Clin Virol"},{"key":"1068_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1440-1746.2009.06006.x","volume":"25","author":"LW Chen","year":"2010","unstructured":"Chen LW, Chien RN, Yen CL, Chang JJ, Liu CJ, Lin CL: Therapeutic Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Occult Hepatitis B Virus Dual infection. J Gastroenterol Hepatol 2010, 25: 259-263. 10.1111\/j.1440-1746.2009.06006.x","journal-title":"J Gastroenterol Hepatol"},{"key":"1068_CR20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/jmv.21695","volume":"82","author":"M Levast","year":"2010","unstructured":"Levast M, Larrat S, Thelu MA, Nicod S, Plages A, Cheveau A, Zarski JP, Seigneurin JM, Mornad P: Prevalenc and Impact of Occult Hepatitis B Infection in Chronic Hepatitis C Patients treated with Pegylated Interferon and Ribavirin. J Med Virol 2010, 82: 747-754. 10.1002\/jmv.21695","journal-title":"J Med Virol"},{"key":"1068_CR21","first-page":"1","volume":"3","author":"M Attia","year":"1998","unstructured":"Attia M: Prevalence of hepatitis B and C in Egypt and Africa. Antivir Ther 1998, 3: 1-9.","journal-title":"Antivir Ther"},{"key":"1068_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jhep.2006.10.007","volume":"46","author":"G Raimondo","year":"2007","unstructured":"Raimondo G, Pollicino T, Cacciola I, Squadrito G: Occult hepatitis B virus infection. J Hepatol 2007, 46: 160-170. 10.1016\/j.jhep.2006.10.007","journal-title":"J Hepatol"},{"key":"1068_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/rmv.569","volume":"18","author":"V Carreno","year":"2008","unstructured":"Carreno V, Bartolome J, Castillo I, Quiroga J: Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol 2008, 18: 139-157. 10.1002\/rmv.569","journal-title":"Rev Med Virol"},{"key":"1068_CR24","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1128\/JVI.67.10.5823-5832.1993","volume":"67","author":"C Shih","year":"1993","unstructured":"Shih C, Lo S, Miyamura T, Chen S, Lee Y: Suppression of Hepatitis B Virus Expression and Replication by Hepatitis C Virus Core Protein in HuH-7 Cells. J Virol 1993, 67: 5823-5832.","journal-title":"J Virol"},{"key":"1068_CR25","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of chronic hepatitis B J Hepatol 2009, 50: 227-242. 10.1016\/j.jhep.2008.10.001","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"1068_CR26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/jmv.21233","volume":"80","author":"H Zaaijer","year":"2008","unstructured":"Zaaijer H, Torres P, Ontanon A, Ponte L, Koppelman M, Lelie P, van Hemert F, Boot H: Multiple surface antigen mutations in five blood donors with occult hepatitis B virus infection. J Med Virol 2008, 80: 1344-1349. 10.1002\/jmv.21233","journal-title":"J Med Virol"},{"key":"1068_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/rmv.569","volume":"18","author":"V Carreno","year":"2008","unstructured":"Carreno V, Bartolome J, Castillo I, Quiroga J: Occult hepatitis B virus and hepatitis C virus infections. Rev Med Virol 2008, 18: 139-157. 10.1002\/rmv.569","journal-title":"Rev Med Virol"},{"key":"1068_CR28","first-page":"46","volume":"6","author":"CL Giudice","year":"2008","unstructured":"Giudice CL, Martinengo M, Pietrasanta P, Bocciardo L, Malavasi C, Rastelli S, Faraci M, Tripodi G: Occult hepatitis B virus infection: A case of reactivation in a patient receiving immunosuppressive treatment for allogeneic bone marrow transplantation. Blood Transfus 2008, 6: 46-50.","journal-title":"Blood Transfus"},{"key":"1068_CR29","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1001\/archinte.1993.00410190107012","volume":"153","author":"RB Schifman","year":"1993","unstructured":"Schifman RB, Rivers SL, Sampliner RE, Krammes JE: Significance of isolated hepatitis C core antibody in blood donors. Arch Intern Med 1993, 153: 2261-2266. 10.1001\/archinte.153.19.2261","journal-title":"Arch Intern Med"},{"key":"1068_CR30","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1053\/jhep.2003.50171","volume":"37","author":"N Yuki","year":"2003","unstructured":"Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura M, Hikiji K, Kato M: Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003, 37: 1172-1179. 10.1053\/jhep.2003.50171","journal-title":"Hepatology"},{"key":"1068_CR31","first-page":"15","volume":"2","author":"A El-Shaarawy","year":"2007","unstructured":"El-Shaarawy A, Abdel Aziz M, Abdel Rahman S, Rageh E, El-Saharnouby A: HCV Genotype and \"Silent\" HBV coinfection: Two main risk factors for a more severe liver disease. Tanta Medi Sci J 2007, 2: 15-26.","journal-title":"Tanta Medi Sci J"},{"key":"1068_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s15010-001-0010-8","volume":"29","author":"A Zekri","year":"2001","unstructured":"Zekri A, Bahnassy A, Ramadan A, El-Bassuoni M, Badran A, Madwar MA: Hepatitis C genotyping versus serotyping in Egyptian patients. Infection 2001, 29: 24-36. 10.1007\/s15010-001-0010-8","journal-title":"Infection"},{"key":"1068_CR33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.510230301","volume":"23","author":"J Kato","year":"1996","unstructured":"Kato J, Hasegawa K, Torii N, Yamaguchi K, Hayashi N: A molecular analysis of viral persistence in surface antigen-negative chronic hepatitis B. Hepatology 1996, 23: 389-395. 10.1002\/hep.510230301","journal-title":"Hepatology"},{"key":"1068_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1386-6532(03)00117-3","volume":"29","author":"P Fabris","year":"2004","unstructured":"Fabris P, Brown D, Tositti G, Bozzola L, Giordani MT, Bevilacqua P, de Lalla F, Webster GJ, Dusheiko G: Occult hepatitis B virus infection does not affect liver histology orresponse to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 2004, 29: 160-166. 10.1016\/S1386-6532(03)00117-3","journal-title":"J Clin Virol"},{"key":"1068_CR35","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1089\/jir.1997.17.449","volume":"17","author":"YF Liaw","year":"1997","unstructured":"Liaw YF, Chien RN, Lin SM, Yeh CT, Tsai SL, Sheen S, Chu CM: Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. J Interferon Cytokine Res 1997, 17: 449-452. 10.1089\/jir.1997.17.449","journal-title":"J Interferon Cytokine Res"},{"key":"1068_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jcv.2005.07.003","volume":"35","author":"C Hui","year":"2006","unstructured":"Hui C, Laub E, Wu H, Montob A, Kimb M, Lukd J, Lau G, Wright T: Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol 2006, 35: 185-192. 10.1016\/j.jcv.2005.07.003","journal-title":"J Clin Virol"},{"key":"1068_CR37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s12072-009-9147-9","volume":"3","author":"CJ Liu","year":"2009","unstructured":"Liu CJ, Chen PJ, Chen DS: Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int 2009, 3: 517-525. Published online: 8 August 2009. Asian Pacific Association for the Study of the Liver 2009 [ http:\/\/www.springerlink.com\/content\/g8086332052jq5w6\/fulltext.html ] 10.1007\/s12072-009-9147-9","journal-title":"Hepatol Int"},{"key":"1068_CR38","first-page":"94","volume":"8","author":"A El-Zayadi","year":"2007","unstructured":"El-Zayadi A: Hepatitis B Virus infection: The Egyptian Situation. Arab J Gastroenterol 2007, 8: 94-98.","journal-title":"Arab J Gastroenterol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-7-324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1743-422X-7-324\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-7-324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T11:39:59Z","timestamp":1592134799000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-7-324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,17]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-7-324","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,17]]},"article-number":"324"}}